The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 26, 2022

Filed:

Apr. 02, 2018
Applicant:

Roche Diagnostics Operations, Inc., Indianapolis, IN (US);

Inventors:

Andrea Horsch, Lucern, CH;

Birgit Klapperich, Risch, CH;

Dirk Block, Bichl, DE;

Alfred Engel, Weilheim, DE;

Johann Karl, Peissenberg, DE;

Rosemarie Kientsch-Engel, Feldafing, DE;

Ekaterina Manuilova, Penzberg, DE;

Christina Rabe, Bad Heilbrunn, DE;

Sandra Rutz, Munich, DE;

Monika Soukupova, Wessobrunn, DE;

Ursula-Henrike Wienhues-Thelen, Krailling, DE;

Peter Kastner, Staffelsee, DE;

Edelgard Anna Kaiser, Huennenberg See, CH;

Assignee:

Roche Diagnostics Operations, Inc., Indianapolis, IN (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/53 (2006.01); G01N 33/68 (2006.01); G01N 33/74 (2006.01);
U.S. Cl.
CPC ...
G01N 33/6893 (2013.01); G01N 33/68 (2013.01); G01N 33/74 (2013.01); G01N 2333/47 (2013.01); G01N 2333/8139 (2013.01); G01N 2800/347 (2013.01); G01N 2800/50 (2013.01);
Abstract

The present disclosure describes a method for predicting the risk of a patient to suffer from acute kidney injury (AKI) during or after a surgical procedure or after administration of a contrast medium. The method is based on the determination of the level of the biomarker IGFBP7 (Insulin-like Growth Factor Binding Protein 7) in a body fluid sample obtained from the patient prior to the surgical procedure or prior to the administration of a contrast medium. Further, the present disclosure describes a method for predicting the risk of a patient to suffer from acute kidney injury (AKI) based on the determination of the amount of the biomarker IGFBP7 (Insulin-like Growth Factor Binding Protein 7) and Cystatin C in a body fluid sample obtained from the patient. The present disclosure further encompasses kits and devices adapted to carry out the methods of the disclosed methods.


Find Patent Forward Citations

Loading…